Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Leo Pharma takes stake in Klox, enters dermatology device market

Executive Summary

Leo Pharma AS (mainly skin diseases; also has a thrombosis portfolio) acquired an undisclosed stake in Canadian device company Klox Technologies Inc. and received worldwide clinical development, manufacturing, and commercialization rights to dermatology devices, including LumiCleanse, incorporating Klox’s BioPhotonic technology. Their alliance excludes Canada where Klox has already partnered with NovartisSandoz.
Deal Industry
  • Medical Devices
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Includes Contract
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies